PMVP · Insider Trading
PMV Pharmaceuticals, Inc
Every open-market purchase and sale reported by PMVP officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-05 | Matthew Joseph Eckler | Director | A | +84,000 deriv. | — |
| 2026-06-05 | Laurie Stelzer | Director | A | +42,000 deriv. | — |
| 2026-06-05 | Arnold J Levine | Director | A | +42,000 deriv. | — |
| 2026-06-05 | Kirsten Flowers | Director | A | +42,000 deriv. | — |
| 2026-06-05 | Charles M Baum | Director | A | +42,000 deriv. | — |
| 2026-06-05 | Carol Giltner Gallagher | Director | MIXED | +42,000 deriv. | — |
| 2026-03-09 | Robert Ticktin | General Counsel & COO | A | +319,270 deriv. | — |
| 2026-03-09 | David Henry Mack | President and CEO | A | +744,960 deriv. | — |
| 2026-03-09 | Deepika Jalota | Chief Development Officer | A | +303,310 deriv. | — |
| 2026-03-09 | Michael Carulli | Chief Financial Officer | A | — | — |
| 2025-10-29 | David Henry Mack | President and CEO | M | +220,643 | +$302.28K |
| 2025-10-27 | OrbiMed Capital GP V LLC | 10%+ Owner | Sell | −2,000,000 | −$3.04M |
| 2025-09-12 | OrbiMed Capital GP V LLC | 10%+ Owner | Sell | −1,000,000 | −$1.80M |
| 2025-07-03 | Robert Ticktin | General Counsel & COO | Sell | −23,151 | −$24.65K |
| 2025-07-03 | Deepika Jalota | Chief Development Officer | Sell | −33,065 | −$35.20K |
| 2025-07-03 | Michael Carulli | Chief Financial Officer | Sell | −28,249 | −$30.08K |
| 2025-07-03 | David Henry Mack | President and CEO | Sell | −58,411 | −$62.18K |
| 2025-06-09 | Laurie Stelzer | Director | A | +33,500 deriv. | — |
| 2025-06-09 | Charles M Baum | Director | A | +33,500 deriv. | — |
| 2025-06-09 | Richard A. Heyman | Director | A | +33,500 deriv. | — |
| 2025-06-09 | Arnold J Levine | Director | A | +33,500 deriv. | — |
| 2025-06-09 | Carol Giltner Gallagher | Director | MIXED | +33,500 deriv. | — |
| 2025-06-09 | Kirsten Flowers | Director | A | +33,500 deriv. | — |
| 2025-03-05 | Deepika Jalota | Chief Development Officer | A | — | — |
| 2025-03-05 | David Henry Mack | President and CEO | A | — | — |
| 2025-03-05 | Michael Carulli | Chief Financial Officer | A | +265,000 deriv. | — |
| 2025-01-22 | David Henry Mack | President and CEO | M | +109,459 | +$58.01K |
| 2024-10-03 | Michael Carulli | Chief Financial Officer | MIXED | — | — |
| 2024-10-03 | David Henry Mack | President and CEO | MIXED | — | — |
| 2024-10-03 | Deepika Jalota | Chief Development Officer | MIXED | — | — |
| 2024-09-12 | Deepika Jalota | Chief Development Officer | Sell | −7,218 | −$10.85K |
| 2024-09-12 | Michael Carulli | Chief Financial Officer | Sell | −2,891 | −$4.35K |
| 2024-06-10 | Charles M Baum | Director | A | +67,500 deriv. | — |
| 2024-06-10 | Richard A. Heyman | Director | A | +67,500 deriv. | — |
| 2024-06-10 | Arnold J Levine | Director | A | +67,500 deriv. | — |
| 2024-06-10 | Laurie Stelzer | Director | A | +67,500 deriv. | — |
| 2024-06-10 | Kirsten Flowers | Director | A | +67,500 deriv. | — |
| 2024-06-10 | Carol Giltner Gallagher | Director | MIXED | +67,500 deriv. | — |
| 2024-01-22 | Deepika Jalota | Chief Development Officer | A | +95,555 | — |
| 2024-01-22 | Michael Carulli | Chief Financial Officer | A | +82,220 | — |
| 2024-01-22 | David Henry Mack | President and CEO | A | +163,890 | — |
| 2023-11-24 | OrbiMed Genesis GP LLC | 10%+ Owner | Sell | −263,358 | −$587.29K |
| 2023-11-13 | David Henry Mack | President and CEO | MIXED | +198,407 | +$105.16K |
| 2023-09-18 | Deepika Jalota | Chief Development Officer | Sell | −4,104 | −$27.17K |
| 2023-09-18 | Leila Alland | Chief Medical Officer | Sell | −6,291 | −$41.65K |
| 2023-08-08 | David Henry Mack | President and CEO | M | +85,500 | +$45.31K |
| 2023-06-12 | Richard A. Heyman | Director | A | +21,500 deriv. | — |
| 2023-06-12 | Kirsten Flowers | Director | A | +21,500 deriv. | — |
| 2023-06-12 | Charles M Baum | Director | A | +21,500 deriv. | — |
| 2023-06-12 | Laurie Stelzer | Director | A | +21,500 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| OrbiMed Capital GP V LLC | Director | 4,975,291 | $5.62M |
| David Henry Mack | President and CEO | 904,691 | $1.02M |
| Arnold J Levine | Director | 409,842 | $463.12K |
| Robert Ticktin | General Counsel & COO | 98,695 | $111.53K |
| Deepika Jalota | Chief Development Officer | 89,959 | $101.65K |
| Michael Carulli | Chief Financial Officer | 73,848 | $83.45K |
| Richard A. Heyman | Director | 975 | $1.10K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the PMVP quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.